Literature DB >> 8151461

Biology and treatment of acute lymphoblastic leukemia.

C H Pui1, W M Crist.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8151461     DOI： 10.1016/s0022-3476(05)83125-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  6 in total

1.  In vitro cleavage of the MLL gene by topoisomerase II inhibitor (etoposide) in normal cord and peripheral blood mononuclear cells.

Authors:  Eiichi Ishii; Mariko Eguchi; Minenori Eguchi-Ishimae; Nobuyuki Yoshida; Megumi Oda; Masafumi Zaitsu; Ichiro Fujita; Sumio Miyazaki; Yuhei Hamasaki; Shuki Mizutani
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

2.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Authors:  E Masson; M V Relling; T W Synold; Q Liu; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

3.  Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome.

Authors:  M Kumagai; A Manabe; C H Pui; F G Behm; S C Raimondi; M L Hancock; H Mahmoud; W M Crist; D Campana
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

4.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

Authors:  T W Synold; M V Relling; J M Boyett; G K Rivera; J T Sandlund; H Mahmoud; W M Crist; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

5.  Molecular cytogenetics in childhood acute lymphoblastic leukemia: a hospital-based observational study.

Authors:  Aakash Pandita; Rekha Harish; Sanjeev K Digra; Alok Raina; Annie Arvind Sharma; Ashwani Koul
Journal:  Clin Med Insights Oncol       Date:  2015-03-24

6.  Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity.

Authors:  Samanta Romina Zanetti; Paola Alejandra Romecin; Meritxell Vinyoles; Manel Juan; José Luis Fuster; Mireia Cámos; Sergi Querol; Mario Delgado; Pablo Menendez
Journal:  J Immunother Cancer       Date:  2020-08       Impact factor: 13.751
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.